Saturday, April 06, 2024 12:18:27 AM
Founded in 2011, Elicio Therapeutics, Inc. ELTX is developing treatment options aimed at significantly improving the quality of life for cancer patients through the utilization of precision vaccines, immunomodulators and cell-based therapies to potentially assemble cancer-killing immune responses against solid tumors.
The company is optimistic about the potential of lymph node-targeting made possible by applying the natural trafficking pathways of larger molecules. This approach differentiates Elicio from its competitors and could be highly promising for enhancing anti-tumor immune responses and improving therapeutic efficacy.
Developed at the Massachusetts Institute of Technology (MIT), the company's proprietary Amphiphile or "AMP" platform, which combines expertise in materials science and immunology, is being used to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Here's how it works:
The AMP platform is designed to deliver therapeutic payloads directly to critical immune cells in the lymph nodes, enhancing the cancer-fighting mechanisms of the immune system. By delivering cancer immunotherapies to the center of the immune response, this approach is intended to optimize the natural ability of the lymph nodes to educate, activate and amplify cancer-specific T cells.
Engineered to coordinate immunity in these uniquely potent sites, the AMP platform was built to amplify the magnitude, potency, quality and durability of the immune response to drive antitumor activity.
At the injection site, the platform prevents detrimental payload delivery to systemic circulation, instead guiding the payloads into the lymphatics to promote lymph node delivery. Additionally, it preserves the structural integrity and activity of payloads by preventing any degradation prior to uptake by lymph node resident immune cells.
Upon reaching the lymph nodes, the platform optimizes retention and directs the delivery of payloads to key immune cells responsible for the coordination of immune responses, specifically the activation and amplification of cancer-specific immune cells in lymph nodes.
Overall, Elicio Therapeutics anticipates that the AMP platform could potentially provide a better quality of life to patients during treatment. The strategy is set apart from other treatments by its ability to activate immune mechanisms directly in the lymph nodes. Enhanced T cell infiltration into tumors, improved T cell expansion and persistence, potent anti-tumor T cell function and wide breadth of response are key attributes with the potential to improve efficacy and reduce the risk of resistance to therapy.
Moving forward, Elicio Therapeutics is committed to developing its lymph node-targeting approach for deployment across a range of vaccines, immunomodulators and adjuvants — training the immune system to put the best cells forward to fight a broad spectrum of cancers.
Recent ELTX News
- Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/25/2024 12:30:00 PM
- Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting • GlobeNewswire Inc. • 04/05/2024 08:30:00 PM
- Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 03/29/2024 12:30:00 PM
- Elicio Therapeutics Announces $6.0 Million Private Placement Financing • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/05/2024 01:30:00 PM
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors • GlobeNewswire Inc. • 01/25/2024 02:00:00 PM
- Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium • GlobeNewswire Inc. • 01/17/2024 01:30:00 PM
- Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 • GlobeNewswire Inc. • 01/09/2024 11:00:00 AM
- Elicio Therapeutics Announces $7.0 Million Private Placement Financing • GlobeNewswire Inc. • 12/22/2023 02:00:32 PM
- Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 12/04/2023 01:00:00 PM
- Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
- Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting • GlobeNewswire Inc. • 11/03/2023 08:30:00 PM
- Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer • GlobeNewswire Inc. • 09/27/2023 09:30:00 PM
- Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines • GlobeNewswire Inc. • 09/07/2023 12:00:00 PM
- Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 12:00:00 PM
- Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics • GlobeNewswire Inc. • 08/28/2023 12:00:00 PM
- Elicio Therapeutics Reports Inducement Grants • GlobeNewswire Inc. • 08/22/2023 08:30:00 PM
- Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 08/11/2023 12:30:54 PM
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model • GlobeNewswire Inc. • 08/09/2023 12:00:00 PM
- Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update • GlobeNewswire Inc. • 06/06/2023 12:00:00 PM
- Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting • GlobeNewswire Inc. • 06/03/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM